1921
Volume 95, Issue 6
  • ISSN: 0002-9637
  • E-ISSN: 1476-1645

Abstract

Abstract

Drug susceptibility testing using molecular techniques can enhance the identification of drug-resistant . Two multiplex real-time polymerase chain reaction (qPCR) assays were developed to detect the most common resistance-associated mutations to isoniazid (S315T, -15C → T), and rifampicin (H526Y and S531L). To assess the species specificity of the qPCR, we selected 31 nontuberculous mycobacteria (NTM) reference strains belonging to 17 species from the public collection of mycobacterial cultures (BCCM/ITM). Additionally, we tested 17 isoniazid and/or rifampicin-resistant strains with other mutations in the target genes to assess mutation specificity. The limit of detection for all the targeted mutations was 20 bacilli/reaction. Multiplex 1 showed 90%, 95%, and 100% efficiency for wild type (WT), Mut 315T, and Mut 531L, respectively; whereas Multiplex 2 showed 97%, 94%, and 90% efficiency for WT, Mut -15, and Mut 526Y, respectively. Three of 17 strains that presented other mutations in the target genes were identified as rifampicin resistant and only 3/31 NTM showed a similar melting temperature to L531 and/or T315 mutants. Thus, our proposed cascade of specific tuberculosis detection followed by drug resistance testing showed sensitivities for 315T, 531L, 526Y, and -15 detection of 100%, 100%, 100%, and 96%, respectively; and specificities of 98%, 95%, 100%, and 100, respectively.

Loading

Article metrics loading...

/content/journals/10.4269/ajtmh.16-0120
2016-12-07
2018-04-20
Loading full text...

Full text loading...

/deliver/fulltext/14761645/95/6/1257.html?itemId=/content/journals/10.4269/ajtmh.16-0120&mimeType=html&fmt=ahah

References

  1. World Health Organization, 2013. The Top 10 Causes of Death. Geneva, Switzerland: WHO. Available at: http://www.who.int/mediacentre/factsheets/fs310/en/.
  2. World Health Organization, 2014. Global Tuberculosis Report 2014. Geneva, Switzerland: WHO.
  3. Silva MS, Senna SG, Ribeiro MO, Valim AR, Telles MA, Kritski A, Morlock GP, Cooksey RC, Zaha A, Rossetti ML, , 2003. Mutations in katG, inhA, and ahpC genes of Brazilian isoniazid-resistant isolates of Mycobacterium tuberculosis . J Clin Microbiol 41: 44714474.[Crossref]
  4. Ramaswamy SV, Reich R, Dou S-J, Jasperse L, Pan X, Wanger A, Quitugua T, Graviss EA, , 2003. Single nucleotide polymorphisms in genes associated with isoniazid resistance in Mycobacterium tuberculosis . Antimicrob Agents Chemother 47: 12411250.[Crossref]
  5. Vilcheze C, Wang F, Arai M, Hazbon MH, Colangeli R, Kremer L, Weisbrod TR, Alland D, Sacchettini JC, Jacobs WR, , 2006. Transfer of a point mutation in Mycobacterium tuberculosis inhA resolves the target of isoniazid. Nat Med 12: 10271029.[Crossref]
  6. Ahmad S, Mokaddas E, , 2009. Recent advances in the diagnosis and treatment of multidrug-resistant tuberculosis. Respir Med 103: 17771790.[Crossref]
  7. Telenti A, Imboden P, Marchesi F, Lowrie D, Cole S, Colston M, Matter L, Schopfer K, Bodmer T, , 1993. Detection of rifampicin-resistance mutations in Mycobacterium tuberculosis . Lancet 341: 647650.[Crossref]
  8. Caws M, Minh Duy P, Quang Tho D, Thi Ngoc Lan N, Viet Hoa D, Farrar J, , 2006. Mutations prevalent among rifampin- and isoniazid-resistant Mycobacterium tuberculosis isolates from a hospital in Vietnam. J Clin Microbiol 44: 23332337.[Crossref]
  9. Asencios L, Galarza M, Quispe N, Vásquez L, Leo E, Valencia E, Ramírez J, Acurio M, Salazar R, Mendoza-Ticona A, Cáceres O, , 2012. Molecular test genotype® MTBDRplus, an alternative to rapid detection of multidrug resistance tuberculosis. Rev Peru Med Exp Salud Publica 29: 9298.[Crossref]
  10. De Freitas FAD, Bernardo V, Gomgnimbou MK, Sola C, Siqueira HR, Pereira MAS, Fandinho FCO, Gomes HM, Araújo MEI, Suffys PN, Marques EA, Albano RM, , 2014. Multidrug resistant Mycobacterium tuberculosis: a retrospective katG and rpoB mutation profile analysis in isolates from a reference center in Brazil. PLoS One 9: e10400.
  11. Murphy K, Berg K, , 2003. Mutation and single nucleotide polymorphism detection using temperature gradient capillary electrophoresis. Expert Rev Mol Diagn 3: 811818.[Crossref]
  12. Scarpellini P, Carrera P, Cichero P, Gelfi C, Gori A, Ferrari M, Zingale A, Lazzarin A, , 2003. Detection of resistance to isoniazid by denaturing gradient-gel electrophoresis DNA sequencing in Mycobacterium tuberculosis clinical isolates. New Microbiol 26: 345351.
  13. Sougakoff W, Rodrigue M, Truffot-Pernot C, Renard M, Durin N, Szpytma M, Vachon R, Troesch A, Jarlier V, , 2004. Use of a high-density DNA probe array for detecting mutations involved in rifampicin resistance in Mycobacterium tuberculosis . Clin Microbiol Infect 10: 289294.[Crossref]
  14. Mccammon MT, Gillette JS, Thomas DP, Ramaswamy SV, Graviss EA, Kreiswirth BN, Vijg J, Quitugua TN, , 2005. Detection of rpoB mutations associated with rifampin resistance in Mycobacterium tuberculosis using denaturing gradient gel electrophoresis. Antimicrob Agents Chemother 49: 22002209.[Crossref]
  15. Isfahani BN, Tavakoli A, Salehi M, Tazhibi M, , 2006. Detection of rifampin resistance patterns in Mycobacterium tuberculosis strains isolated in Iran by polymerase chain reaction-single-strand conformation polymorphism and direct sequencing methods. Mem Inst Oswaldo Cruz 101: 597602.[Crossref]
  16. Shi R, Zhang J, Li C, Kazumi Y, Sugawara I, , 2007. Detection of streptomycin resistance in Mycobacterium tuberculosis clinical isolates from China as determined by denaturing HPLC analysis and DNA sequencing. Microbes Infect 9: 15391544.[Crossref]
  17. Wittwer CT, , 2009. High-resolution DNA melting analysis: advancements and limitations. Hum Genome Var Soc 30: 857859.
  18. Pérez-Osorio AC, Boyle DS, Ingham ZK, Ostash A, Gautom RK, Colombel C, Houze Y, Leader BT, , 2011. Rapid identification of mycobacteria and drug-resistant Mycobacterium tuberculosis by use of a single multiplex PCR and DNA sequencing. J Clin Microbiol 50: 326336.[Crossref]
  19. Mayta H, Gilman RH, Arenas F, Valencia T, Caviedes L, Montenegro SH, Ticona E, Ortiz J, Chumpitaz R, Evans CA, Williams DL, , 2003. Evaluation of a PCR-based universal heteroduplex generator assay as a tool for rapid detection of multidrug-resistant Mycobacterium tuberculosis in Peru. J Clin Microbiol 41: 57745777.[Crossref]
  20. Montenegro SH, Gilman RH, Sheen P, Cama R, Caviedes L, Hopper T, Chambers R, Oberhelman RA, , 2003. Improved detection of Mycobacterium tuberculosis in Peruvian children by use of a heminested IS6110 polymerase chain reaction assay. Clin Infect Dis 36: 1623.[Crossref]
  21. Lacoma A, Garcia-Sierra N, Prat C, Ruiz-Manzano J, Haba L, Rosés S, Maldonado J, Domínguez J, , 2008. GenoType MTBDRplus assay for molecular detection of rifampin and isoniazid resistance in Mycobacterium tuberculosis strains and clinical samples. J Clin Microbiol 46: 36603667.[Crossref]
  22. Canetti G, Fox W, Khomenko A, Mahler HT, Menon NK, Mitchison DA, Rist N, Smelev NA, , 1969. Advances in techniques of testing mycobacterial drug sensitivity, and the use of sensitivity tests in tuberculosis control programmes. Bull World Health Organ 41: 2143.
  23. Grange JM, Yates MD, de Kantor IN, . Guidelines for Speciation within the Mycobacterium tuberculosis Complex, 2nd edition. Geneva, Switzerland: World Health Organization.
  24. Kremer K, van Soolingen D, Frothingham R, Haas WH, Hermans PWM, Martín C, Palittapongarnpim P, Plikaytis BB, Riley LW, Yakrus MA, Musser JM, van Embden JDA, , 1999. Comparison of methods based on different molecular epidemiological markers for typing of Mycobacterium tuberculosis complex strains: interlaboratory study of discriminatory power and reproducibility. J Clin Microbiol 37: 26072618.
  25. Barletta F, Vandelannoote K, Collantes J, Evans CA, Arevalo J, Rigouts L, , 2014. Standardization of a TaqMan-based real-time PCR for the detection of Mycobacterium tuberculosis-complex in human sputum. Am J Trop Med Hyg 91: 709714.[Crossref]
  26. Van Embden JDA, Cave MD, Crawford JT, Dale JW, Eisenach KD, Gicquel B, Hermans P, Martin C, Mcadam R, Shinnick TM, Small PM, , 1993. Strain identification of Mycobacterium tuberculosis by DNA fingerprinting: recommendations for a standardized methodology. J Clin Microbiol 31: 406409.
  27. Käser M, Ruf M-T, Hauser J, Marsollier L, Pluschke G, , 2009. Optimized method for preparation of DNA from pathogenic and environmental mycobacteria. Appl Environ Microbiol 75: 414418.[Crossref]
  28. Newcombe RG, , 1998. Two-sided confidence intervals for the single proportion: comparison of seven methods. Stat Med Stat Med 17: 857872.[Crossref]
  29. Mokrousov I, Narvskaya O, Otten T, Limeschenko E, Steklova L, Vyshnevskiy B, , 2002. High prevalence of KatG Ser315Thr substitution among isoniazid-resistant Mycobacterium tuberculosis clinical isolates from northwestern Russia, 1996 to 2001. Antimicrob Agents Chemother 46: 14171424.[Crossref]
  30. Nikolayevsky V, Brown T, Balabanova Y, Ruddy M, Fedorin I, Drobniewski F, , 2004. Detection of mutations associated with isoniazid and rifampin resistance in Mycobacterium tuberculosis isolates from Samara Region, Russian Federation. J Clin Microbiol 42: 44984502.[Crossref]
  31. Seifert M, Catanzaro D, Catanzaro A, Rodwell TC, , 2015. Genetic mutations associated with isoniazid resistance in Mycobacterium tuberculosis: a systematic review. PLoS One 10: e0119628.[Crossref]
  32. Ramaswamy S, Musser J, , 1998. Molecular genetic basis of antimicrobial agent resistance in Mycobacterium tuberculosis: 1998 update. Tuber Lung Dis 79: 329.[Crossref]
  33. Valim AR, Rossetti ML, Ribeiro MO, Zaha A, , 2000. Mutations in the rpoB gene of multidrug-resistant Mycobacterium tuberculosis isolates from Brazil. J Clin Microbiol 38: 31193122.
  34. Somoskovi A, Parsons LM, Salfinger M, , 2001. The molecular basis of resistance to isoniazid, rifampin, and pyrazinamide in Mycobacterium tuberculosis . Respir Res 2: 164168.[Crossref]
  35. Cavusoglu C, Karaca-Derici Y, Bilgic A, , 2004. In-vitro activity of rifabutin against rifampicin-resistant Mycobacterium tuberculosis isolates with known rpoB mutations. Clin Microbiol Infect 10: 662665.[Crossref]
  36. Van Deun A, Aung KJM, Bola V, Lebeke R, Hossain MA, de Rijk WB, Rigouts L, Gumusboga A, Torrea G, de Jong BC, , 2013. Rifampin drug resistance tests for tuberculosis: challenging the gold standard. J Clin Microbiol 51: 26332640.[Crossref]
  37. Bustin SA, Benes V, Garson JA, Hellemans J, Huggett J, Kubista M, Mueller R, Nolan T, Pfaffl MW, Shipley GL, Vandesompele J, Wittwer CT, , 2009. The MIQE guidelines: minimum information for publication of quantitative real-time PCR experiments. Clin Chem 55: 611622.[Crossref]
  38. Helb D, Jones M, Story E, Boehme C, Wallace E, Ho K, Kop J, Owens MR, Rodgers R, Banada P, Safi H, Blakemore R, Lan NTN, Jones-López EC, Levi M, Burday M, Ayakaka I, Mugerwa RD, Mcmillan B, Winn-Deen E, Christel L, Dailey P, Perkins MD, Persing DH, Alland D, , 2010. Rapid detection of Mycobacterium tuberculosis and rifampin resistance by use of on-demand, near-patient technology. J Clin Microbiol 48: 229237.[Crossref]
  39. Richter E, Weizenegger M, Fahr A-M, Rüsch-Gerdes S, , 2004. Usefulness of the GenoType MTBC assay for differentiating species of the Mycobacterium tuberculosis complex in cultures obtained from clinical specimens. J Clin Microbiol 42: 43034306.[Crossref]
  40. Moure R, Muñoz L, Torres M, Santin M, Martín R, Alcaide F, , 2011. Rapid Detection of Mycobacterium tuberculosis complex and rifampin resistance in smear-negative clinical samples by use of an integrated real-time PCR method. J Clin Microbiol 49: 11371139.[Crossref]
  41. Rigouts L, Gumusboga M, de Rijk WB, Nduwamahoro E, Uwizeye C, de Jong B, Van Deun A, , 2013. Rifampin resistance missed in automated liquid culture system for Mycobacterium tuberculosis isolates with specific rpoB mutations. J Clin Microbiol 51: 26412645.[Crossref]
  42. de Abreu Maschmann R, F, de Souza Nuunes L, Wolowski Ribeiro A, Marcon Machado RT, Zaha A, Rosa Rossetti LM, , 2013. Performance of the GenoType MTBDRplus assay directly on sputum specimens from Brazilian patients with tuberculosis treatment failure or relapse. J Clin Microbiol 51: 16061608.[Crossref]
  43. Steingart KR, Schiller I, Horne DJ, Pai M, Boehme CC, Dendukuri N, , 2014. Xpert® MTB/RIF assay for pulmonary tuberculosis and rifampicin resistance in adults. Cochrane Database Syst Rev 1: CD009593.
  44. Zhao P, Fang F, Yu Q, Guo J, Zhang J-H, Qu J, Liu Y, , 2014. Evaluation of BACTEC MGIT 960 system for testing susceptibility of Mycobacterium tuberculosis to first-line drugs in China. PLoS One 9: e99659.[Crossref]
  45. Ugarte-Gil C, Alvarez MP, Moore DAJ, , 2008. Drug susceptibility tests for Mycobacterium tuberculosis . Acta Med Per 25: 171175.
  46. Hillemann D, Rüsch-Gerdes S, Richter E, , 2007. Evaluation of the GenoType MTBDRplus assay for rifampin and isoniazid susceptibility testing of Mycobacterium tuberculosis strains and clinical specimens. J Clin Microbiol 45: 26352640.[Crossref]
  47. Sheng J, Li J, Sheng G, Yu H, Huang H, Cao H, Lu Y, Deng X, , 2008. Characterization of rpoB mutations associated with rifampin resistance in Mycobacterium tuberculosis from eastern China. J Appl Microbiol 105: 904911.[Crossref]
  48. Ahmad S, Al-Mutairi NM, Mokaddas E, , 2012. Variations in the occurrence of specific rpoB mutations in rifampicin-resistant Mycobacterium tuberculosis isolates from patients of different ethnic groups in Kuwait. Indian J Med Res 135: 756762.
  49. Martín-Casabona N, Bahrmand A, Bennedsen J, Thomsen V, Curcio M, Fauville-Dufaux M, Feldman K, Havelkova M, Katila M, Köksalan K, Pereira M, Rodrigues F, Pfyffer G, Portaels F, Urgell J, Rüsch-Gerdes S, Tortoli E, Vincent V, Watt B, Spanish Group for Non-Tuberculosis Mycobacteria; , 2004. Non-tuberculous mycobacteria: patterns of isolation. A multi-country retrospective survey. Int J Tuberc Lung Dis 8: 11861193.
  50. Marras TK, Chedore P, Ying AM, Jamieson F, , 2007. Isolation prevalence of pulmonary non-tuberculous mycobacteria in Ontario. Thorax 62: 661666.[Crossref]
  51. Marras T, Daley C, , 2002. Epidemiology of human pulmonary infection with nontuberculous mycobacteria. Clin Chest Med 23: 553567.[Crossref]
  52. Hoefsloot W, Van Ingen J, Andrejak C, Ngeby K, Bauriaud R, Bemer P, Beylis N, Boeree MJ, Cacho J, Chihota V, Chimara E, Churchyard G, Cias R, Daza R, Daley CL, Dekhuijzen PNR, Domingo D, Drobniewski F, Esteban J, Fauville-Dufaux M, Folkvardsen DB, Gibbons N, Gómez-Mampaso E, Gonzalez R, Hoffmann H, Hsueh P-R, Indra A, Jagielski T, Jamieson F, Jankovic M, Jong E, Keane J, Koh W-J, Lange B, Leao S, Macedo R, Mannsåker T, Marras TK, Maugein J, Milburn HJ, Mlinkó T, Morcillo N, Morimoto K, Papaventsis D, Palenque E, Paez-Peña M, Piersimoni C, Polanová M, Rastogi N, Richter E, Ruiz-Serrano MJ, Silva A, Pedro Da Silva M, Simsek H, Van Soolingen D, Szabó N, Thomson R, Fernandez TT, Tortoli E, Totten SE, Tyrrell G, Vasankari T, Villar M, Walkiewicz R, Winthrop KL, Wagner D, Van Ingen J, , 2013. The geographic diversity of nontuberculous mycobacteria isolated from pulmonary samples An NTM-NET collaborative study for the Nontuberculous Mycobacteria Network European Trials Group (NTM-NET). Eur Respir 42: 16041613.[Crossref]
  53. Munayco C, Grijalva CG, Culqui DR, Bolarte JL, Suárez-Ognio LA, Neyda Q, Calderoni R, Ascencios L, Del Solar M, Salomón M, Bravo F, Gotuzzo E, , 2008. Outbreak of persistent cutaneous abscesses due to Mycobacterium chelonae after mesotherapy sessions, Lima, Peru. Rev Saude Publica 42: 146149.[Crossref]
  54. Thacker TC, Robbe-Austerman S, Harris B, Van Palmer M, Waters WR, , 2013. Isolation of mycobacteria from clinical samples collected in the United States from 2004 to 2011. BMC Vet Res 9: 100.[Crossref]
  55. Jenkins HE, Zignol M, Cohen T, , 2011. Quantifying the burden and trends of isoniazid resistant tuberculosis, 1994–2009. PLoS One 6: e22927.[Crossref]
  56. Menzies D, Benedetti A, Paydar A, Royce S, Pai M, Burman W, Vernon A, Lienhardt C, , 2009. Standardized treatment of active tuberculosis in patients with previous treatment and/or with mono-resistance to isoniazid: a systematic review and meta-analysis. PLoS Med 6: e1000150.[Crossref]
  57. Jacobson KR, Theron D, Victor TC, Streicher EM, Warren RM, Murray MB, , 2011. Treatment outcomes of isoniazid-resistant tuberculosis patients, Western Cape Province, South Africa. Clin Infect Dis 53: 369372.[Crossref]
  58. Leung ETY, Ho PL, Yuen KY, Woo WL, Lam TH, Kao RY, Seto WH, Yam WC, , 2006. Molecular characterization of isoniazid resistance in Mycobacterium tuberculosis: identification of a novel mutation in inhA. Antimicrob Agents Chemother 50: 10751078.[Crossref]
  59. Van Doorn HR, De Haas PEW, Kremer K, Vandenbroucke-Grauls CMJE, Borgdorff MW, Van Soolingen D, , 2006. Public health impact of isoniazid-resistant Mycobacterium tuberculosis strains with a mutation at amino-acid position 315 of katG: a decade of experience in The Netherlands. Clin Microbiol Infect 12: 769775.[Crossref]
http://instance.metastore.ingenta.com/content/journals/10.4269/ajtmh.16-0120
Loading
/content/journals/10.4269/ajtmh.16-0120
Loading

Data & Media loading...

Supplementary Data

Supplementary PDF

  • Received : 16 Feb 2016
  • Accepted : 25 Aug 2016

Most Cited This Month

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error